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Abstract
Background: Catheter-associated urinary tract infection (CAUTI) is one of the most common hospital-acquired
infections. However, many cases treated as hospital-acquired CAUTI are actually asymptomatic bacteriuria (ABU).
Evidence-based guidelines recommend that providers neither screen for nor treat ABU in most catheterized
patients, but there is a significant gap between these guidelines and clinical practice. Our objectives are (1) to
evaluate the effectiveness of an audit and feedback intervention for increasing guideline-concordant care
concerning catheter-associated ABU and (2) to measure improvements in healthcare providers’ knowledge of and
attitudes toward the practice guidelines associated with the intervention.
Methods/Design: The study uses a controlled pre/post design to test an intervention using audit and feedback of
healthcare providers to improve their compliance with ABU guidelines. The intervention and the control sites are
two VA hospitals. For objective 1 we will review medical records to measure the clinical outcomes of inappropriate
screening for and treatment of catheter-associated ABU. For objective 2 we will survey providers’ knowledge and
attitudes. Three phases of our protocol are proposed: the first 12-month phase will involve observation of the
baseline incidence of inappropriate screening for and treatment of ABU at both sites. This surveillance for clinical
outcomes will continue at both sites throughout the study. Phase 2 consists of 12 months of individualized audit
and feedback at the intervention site and guidelines distribution at both sites. The third phase, also over 12
months, will provide unit-level feedback at the intervention site to assess sustainability. Healthcare providers at the
intervention site during phase 2 and at both sites during phase 3 will complete pre/post surveys of awareness and
familiarity (knowledge), as well as of acceptance and outcome expectancy (attitudes) regarding the relevant
practice guidelines.
Discussion: Our proposal to bring clinical practice in line with published guidelines has significant potential to
decrease overdiagnosis of CAUTI and associated inappropriate antibiotic use. Our study will also provide
information about how to maximize effectiveness of audit and feedback to achieve guideline adherence in the
inpatient setting.
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Urinary tract infection (UTI) is the single most common
hospital-acquired infection, and many cases of nosoco-
mial UTI are associated with an indwelling urinary
catheter [1,2]. Urinary catheters bypass normal host
defenses, and bacteriuria develops at the rate of approxi-
mately 5% per day; [3] nearly all individuals (98%) who
are catheterized for 30 days or longer will have bacter-
iuria caused by one or more species of potentially
pathogenic bacteria [4,5]. Furthermore, organisms caus-
ing catheter-associated urinary tract infection (CAUTI)
are frequently resistant to one or more antibiotics [6,7].
In addition to these concerns regarding quality of care,
annual incremental costs attributed to nosocomial
CAUTI in 2002 were estimated to exceed $451 million
[8]. Finally, since public reporting of nosocomial infec-
tions has become mandated in more than 30 states, [9]
hospitals have strong incentive to reduce their rates of
hospital-acquired CAUTI.
An important distinction exists between CAUTI and
asymptomatic bacteriuria (ABU). CAUTI, as defined by
the US Centers for Disease Control (CDC) and the
National Healthcare Safety Network, involves symptoms
(fever, urgency, frequency, dysuria, or suprapubic tender-
ness), in addition to microorganisms in the urine [10].
CAUTI requires antimicrobial treatment to relieve symp-
toms, while patients with ABU are, by definition, asymp-
tomatic. Treatment of ABU in patients with an
indwelling catheter does not improve morbidity or mor-
tality, nor does it decrease the incidence of symptomatic
CAUTI [11]. Use of antimicrobial agents to prevent or to
treat catheter-associated ABU does lead to emergence of
resistant flora, however [12]. Accordingly, evidence-based
guidelines concerning ABU have stated that it is inap-
propriate to screen for or to treat ABU associated with
the presence of a urinary catheter, with the exceptions of
pregnant women and persons undergoing invasive urolo-
gic procedures [11,13]. The CDC campaign to prevent
antimicrobial resistance in hospitalized patients likewise
instructs clinicians to “treat infection, not colonization.”
[14] Unfortunately, a significant translation gap between
evidence-based guidelines concerning management of
ABU and clinical practice has been observed throughout
the world [15,16]. Overtreatment of ABU is a quality,
safety, and cost issue, particularly as unnecessary antibio-
tics lead to emergence of resistant pathogens [14,17].
Audit and feedback, or providing healthcare profes-
sionals with timely data about their performance, has
proven efficacy as a means to improve quality of care
[18,19]. Two systematic reviews of audit and feedback
concluded that there was no evidence that multifaceted
interventions worked better than did audit and feedback
alone [18,19]. These reviews also suggest that the
structure of the intervention should be tailored to the
local setting and that the intensity of feedback should be
high. More specific information about elements of effec-
tive audit and feedback emerges from a qualitative sur-
vey of the Department of Veterans Affairs (VA) facilities
with either high or low adherence to six clinical practice
guidelines [20]. VA facilities with a high level of guide-
line compliance provided feedback that was frequent/
timely, individualized, nonpunitive, and in some cases,
customizable. Additionally, providing the correct solu-
tion in the feedback appeared to be important [21]. We
plan to build upon these findings using audit and feed-
back first at the individual level and later at the level of
the hospital ward team to improve the implementation
of ABU guidelines into routine care.
Primary objectives and hypotheses
Objective 1
The first objective is to improve quality of care concern-
ing catheter-associated ABU, in terms of clinical out-
comes through implementation of an audit and
feedback strategy at the intervention site. Clinical out-
comes will also be monitored at the control site. Both
sites are tertiary care VA hospitals. We hypothesize that
improving adherence to evidence-based guidelines con-
cerning ABU will decrease the inappropriate use of anti-
biotics to treat catheter-associated ABU (objective 1a)
and will decrease inappropriate screening for ABU
(objective 1b).
Objective 2
Our second objective is to measure increases in clini-
cians’ knowledge of and attitudes towards practice
guidelines associated with the intervention. Domains of
knowledge measured will include awareness of and
familiarity with ABU guidelines. Domains of attitudes
measured will include acceptance of and outcome
expectancy regarding nontreatment of ABU. We
hypothesize that successful implementation of the inter-
vention will improve clinicians’ knowledge of and atti-
tudes towards the guidelines.
Methods
Study design
The study uses a controlled pre/post design to test an
intervention using audit and feedback of healthcare pro-
viders to improve their compliance with ABU guidelines.
The intervention and the control sites are two different
VA hospitals.
Conceptual framework
The conceptual framework for our study (Figure 1) has
been adapted and updated from the Cabana et al. [22]
model of barriers to physician guideline adherence to
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(knowledge), acceptance and outcome expectancy (atti-
tudes), and external barriers [22,23]. The first external
barrier that we will address ist h a tt h ev a r i o u sd e f i n i -
tions of CAUTI and catheter-associated ABU are
obscure, conflicting, and difficult to apply to hospita-
lized patients. The ABU and CAUTI guidelines lack
specific information about how to apply the definitions
of ABU and CAUTI to individual patients. We will
provide this clarity by developing a diagnostic algo-
rithm to distinguish between CAUTI and ABU.
Distributing this guidelines-based algorithm will
address both awareness and familiarity, but guideline dis-
semination alone is not an effective method to achieve
guideline implementation [18,19,24-26]. The audit and
feedback intervention will tackle two points in the chain
of events that leads from a patient at risk to a patient
who receives unnecessary antibiotics for ABU: the deci-
sion to order a urine culture (inappropriate screening)
and the decision to treat a positive urine culture
(inappropriate prescribing). We can measure the clinical
outcomes after each of these points (objective 1); at the
same time, we can measure changes in providers’ knowl-
edge (awareness and familiarity) and attitudes (social
norms, acceptance, risk perceptions, self-efficacy, and
outcome expectancy of ABU guidelines) (objective 2).
The algorithm itself and the instructions on how to use it
(via audit and feedback) will address self-efficacy con-
cerning the guidelines. Lack of outcome efficacy will also
be addressed through the audit and feedback sessions, as
clinicians will be reassured when they see that withhold-
ing inappropriate antibiotics does not lead to harm and
may even benefit their patients. We expect agreement
with and acceptance of guidelines to likewise increase.
We will also identify external barriers to guideline com-
pliance by performing exit interviews with clinicians who
have participated in the study. The conceptual model
depicted in Figure 1 will enable us to determine which
aspects of our implementation protocol are responsible
for the observed changes in clinical outcomes.
Figure 1 conceptual model for treatment of asymptomatic bacteriuria (ABU) and patient health outcomes.O u rc o n c e p t u a lm o d e l
adapts and updates elements of the Cabana model of “Why don’t physicians follow clinical practice guidelines?” to focus on the following
barriers to guideline implementation: awareness and familiarity (knowledge), agreement and outcome expectancy (attitudes), and external
barriers (behavior). The audit-feedback intervention will tackle 2 points in the chain of events that leads from a patient at risk to a patient who
receives unnecessary antibiotics for ABU: the decision to order a urine culture (inappropriate screening) and the decision to treat a positive urine
culture (inappropriate prescribing). We can measure the clinical outcomes after each of these points (objective 1), and at the same time we can
measure changes in providers’ awareness, familiarity, acceptance, and outcomes expectancy of ABU guidelines (objective 2). This conceptual
model will help us determine which aspects of our implementation protocol are responsible for the observed changes in clinical outcomes.
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Our study will occur over three years (see Table 1). Year
1 will be the development phase, year 2 will involve the
implementation of the intervention and the initial pre/
post evaluation, and year 3 will provide follow-up and
evaluation of the sustainability of the intervention.
Throughout the three years of the study, we will per-
form surveillance at both sites for the clinical outcomes
that are the focus of objective 1. Specific hospital units
with low levels of guideline-concordant behavior and
high clinical need for the intervention will be the focus
of our strategy. Also during the first year we will
develop the educational study materials and surveys that
will be used during the second and third years of the
study. These study materials include the CAUTI diag-
nostic algorithm, the audit and feedback intervention
and script, and the surveys to be administered before
and after the intervention.
The intervention will begin in year 2. We will distri-
bute guidelines and definitions concerning ABU and
CAUTI at both sites in the form of a diagnostic algo-
rithm. Guideline distribution to providers will continue
at appropriate intervals at both sites for the ensuing two
years. During the second year, we will provide individua-
lized audit and feedback at the intervention site. The
research team will review episodes of bacteriuria and
the management implemented by the provider who
ordered the urine culture. Research personnel will then
visit the provider to discuss whether his or her behavior
was or was not in compliance with ABU guidelines.
Unit-level feedback will also be given by the research
assistant on a monthly basis by presenting the unit’s
results in graphical form. The unit in this case will be
the five hospital wards for the long-term care patients
and the eight internal medicine teams for the medicine
wards. At the control site, algorithm distribution alone
will occur during the second year. During the second
year, we will also evaluate the effect of the intervention
on the barriers to guidelines implementation in terms of
awareness, familiarity, acceptance, and outcome expec-
tancy through pre/post surveys completed by healthcare
providers at the intervention site. Exit (qualitative) inter-
views with study participants will also address potential
barriers to implementation of our intervention protocol.
During the third year of the study, the individualized
visits to providers will cease, but unit-level feedback will
continue over the course of the third year at the inter-
vention site. During this year, the surveys will be admi-
nistered at the control site in addition to the
intervention site so that we can assess the effect that the
surveys alone have on prescribing behavior and on
responses to survey questions. The purpose of the third
year is to continue to measure elements of the study, as
well as to evaluate issues of sustainability and the mini-
mal intervention elements needed for dissemination.
Setting and participants
Setting
T h ei n t e r v e n t i o ns i t ea n dt h ec o n t r o ls i t e sw e r ec h o s e n
because they are alike in terms of ward organization,
patient population, infection-control software, and clini-
cian and medical resident involvement in patient care.
We also studied the organizational context of the pro-
posed intervention site (MEDVAMC) and control site
(STVHCS) using the results of the VA Clinical Practice
Organizational Survey (CPOS), Chief of Staff Module,
with specific focus on responses to survey elements con-
cerning support for guideline adherence and implemen-
tation of quality improvement measures [27]. Overall, the
two sites are similar in several key elements relevant to
our project. In particular, audit and feedback is not used
extensively at either site and is primarily applied to clini-
cians’ laboratory test ordering. Both sites rely on desig-
nated site champions to implement clinical guidelines or
performance measures, although finding someone willing
to take on this role was difficult at one of these sites
because of time constraints. The leaders at both sites are
strongly committed to continual improvement.
Table 1 overview of study activities at intervention and control sites
Year MEDVAMC (intervention) STVHCS (control)
Year 1 Baseline surveillance Baseline surveillance
Development of study materials (algorithm, surveys, and audit and feedback script)
Qualitative data collection on study materials
Year 2 Ongoing surveillance Ongoing surveillance
Guidelines distribution (algorithm) Guidelines distribution (algorithm)
Intervention: individual audit and feedback
Pre/post surveys
Year 3 Ongoing surveillance Ongoing surveillance
Guidelines distribution (algorithm) Guidelines distribution (algorithm)
Intervention: unit-level feedback
Pre/post surveys Pre/post surveys
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necessary (as opposed to intervening at the ward level)
because medical residents travel throughout the hospital
via consult services and thus, may potentially serve to
diffuse knowledge throughout the facility. Hospital units
at the intervention site with the highest rates of guide-
line-noncompliant behavior were identified, including
the five general medicine wards and the five extended-
care units, where 36.1% of patients received inappropri-
ate treatment. The corresponding units at the control
site have been selected for our study (three medicine
wards and two extended-care wards). The intervention
and control facilities are in different Veterans Integrated
Service Networks, or VISNs, w h i c hi sa d v a n t a g e o u sf o r
s t u d yp u r p o s e s .F o rt h eS T V H C St ob eat r u ec o n t r o l ,
healthcare providers should not overlap or have signifi-
cant work-related communication with the intervention
facility. Also, performing the study in two different
VISNs will ultimately facilitate diffusion of the study
intervention.
Participants
Research team
The research team brings together a diverse group of
members from both sites. The nine investigators include
three infectious diseases physicians, a geriatrician, a
biostatistician, a measurement psychologist, a health
economist, and two industrial/organizational psycholo-
gists. Each site has a research assistant, with oversight
provided by the overall research coordinator for the
study. A programmer works with the team to code the
database, and the research site has dedicated personnel
for research-compliance assurance.
Healthcare providers targeted in the intervention
The audit and feedback intervention will be applied to
the healthcare providers who make the decision to treat
CAUTI. The healthcare provider who makes the deci-
sion to order a urine culture and to prescribe antibiotics
for a positive urine culture differs depending on hospital
unit. In the internal-medicine wards, this decision is
made by internal-medicine residents, who are usually
either interns or second-year residents (postgraduate
year 1 or 2). Approximately 170 medical residents rotate
through the intervention site medicine wards per year.
The extended-care units are staffed by nurse practi-
tioners and physician assistants, with supervision pro-
vided by VA staff physicians trained in geriatrics.
Therefore, in the extended-care ward, the intervention
will target the nurse practitioners, physician assistants,
and staff physicians, currently 17 individuals.
Patients participating in the study
All patients in the targeted study wards at the two sites
are indirectly participating in the study through our sur-
veillance for relevant clinical outcomes. Year 1 of the
study began in July 2010, so we are currently in the
baseline surveillance phase. Reviews of the medical
records are performed for all patients in the study wards
at both sites five days per week; weekend surveillance
results are captured backwards from Monday’s findings.
This review is performed using the VA electronic medi-
cal record, the Clinical Patient Record System (CPRS).
Information collected includes bed-occupancy days, pre-
sence of any type of urinary catheter (indwelling or
Foley, external or condom, intermittent, and suprapu-
bic), whether a urine culture was sent, and the results of
any urine cultures sent. Bedside visits are made in one
ward per month to verify the catheter presence and type
reported in the electronic medical record. Additional
information is collected for each episode of bacteriuria
(≥10
3 organisms/mL of urine). For each episode of bac-
teriuria, we collect information about patient demo-
graphics, the presence/absence of relevant symptoms
and comorbidities, and type/duration of antibiotics
given. We use this information to classify episodes of
bacteriuria as ABU or CAUTI and to determine whether
the provider’s response to the urine culture results was
appropriate or inappropriate. Surveillance data are
stored in Excel (Microsoft Corporation, Seattle, WA,
USA), while the individual episodes of bacteriuria are
detailed in an Access database (Microsoft Corporation,
Seattle, WA, USA), which also uses a computer query to
verify our case classification. We use Theradoc
® (Hos-
pira, Inc., Salt Lake City, UT, USA), a proprietary infec-
tion-control software package used in several VA
hospitals, to extract the information about antibiotic
usage from CPRS.
Intervention
Development of intervention components
As the study is currently in year 1, we are developing,
piloting, and validating the following study materials to
be used in the intervention: a diagnostic algorithm for
CAUTI versus ABU, the audit and feedback script and
intervention, and the pre/post surveys (described in
Data collection below) of guidelines knowledge and atti-
tudes (see Tables 1 and 2).
Diagnostic algorithm
The purpose of the diagnostic algorithm is to operatio-
n a l i z et h e5 3 - p a g eC A U T Ig u idelines and the 11-page
ABU guidelines so that healthcare providers can deter-
mine how to apply these guidelines to their patients.
This algorithm will also be used by research personnel
at both sites to classify episodes of bacteriuria as
CAUTI or ABU and to determine whether use of anti-
biotics for the bacteriuria was appropriate or inappropri-
ate. This algorithm has been reviewed and modified in
accordance with the comments of 8 of 11 experts on
the guidelines panel to establish evidence of content
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interviewing with the target population of healthcare
providers to establish evidence of construct validity.
Further validation efforts will include testing convergent
and predictive validity.
Audit and feedback intervention
The audit and feedback intervention design is closely
linked to the diagnostic algorithm. We are preparing a
script and a visual aid based upon the diagnostic algo-
rithm and the various decision points in this algorithm.
Individualized audit and feedback will be provided to
medical residents during their ward team’sd e s i g n a t e d
educational time and to healthcare providers in the
extended-care line during charting time. Prior to an audit
and feedback visit, the research personnel will prepare a
color-coded version of the algorithm that indicates where
appropriate actions were taken for the episode of bacter-
iuria (green), where decisions were inappropriate (red),
and which decision path would have been guidelines
compliant (blue). An individualized audit and feedback
script will be generated that covers only the decision
nodes relevant to the case. This script will be presented
both in PowerPoint (Microsoft Corporation, Seattle, WA,
USA) and on paper for discussion. The paper copy of the
color-coded algorithm will be given to the healthcare
provider to review, while the contents of the script are
delivered verbally by the research assistant. The informa-
tion content and delivery have been carefully designed to
be supportive rather than punitive, and to provide the
correct answer at each decision node. The delivery of the
audit and feedback script and the color-coded algorithm
will be pilot tested with residents who will graduate prior
to the start of the intervention and with nonphysician
healthcare providers on nonstudy wards.
Ward- and/or team-level feedback will be prepared
and delivered on a monthly basis in the form of colorful
pie charts depicting the percentage of bacteriuria treat-
ment decisions that were or were not guidelines compli-
ant and how each team’s performance compares to that
of other teams. Our study logo will appear on all study
materials to facilitate awareness and recognition of our
campaign.
Outcomes
Objective 1 focuses on the clinical outcomes of inap-
propriate screening for and treatment of catheter-asso-
ciated ABU, as well as on complications of
inappropriately prescribed antibiotics (Table 3). Objec-
tive 2 focuses on measuring changes in knowledge and
attitudes concerning the ABU and CAUTI guidelines
(see Table 2).
Data collection
Surveillance of target hospital wards
Surveillance of all targeted hospital wards will include
regular, systematic chart reviews of medical and nursing
notes to identify each patient with a urinary catheter,
each urine culture ordered on those patients, and the
ordering of antibiotics after urine culture results are
reported. Research personnel have been trained to fol-
low a systematic process of documentation for each of
these measures (described in Table 3), which has been
validated against bedside observation.
Surveys
The survey instrument was created through literature
review, review of existing antimicrobial stewardship pro-
jects, and discussion with investigators conducting
related studies, including studies of UTI and ABU
[28-33]. The survey contains items that measure
Table 2 outcome measures for objective 2
Outcome Measurement strategy Measure of meaningful change
Guidelines awareness Survey questions KA1-KA2
a Raw number and proportion of respondents changing from NO to YES
Guidelines familiarity Survey question KF1
a Average increase from “do not recall” or “minimal recall” to “working familiarity” or
“complete recall”
Guidelines familiarity Survey questions KF2-KF8 Raw number and proportion of respondents changing from SD or D to SA or A
Guidelines familiarity Survey question KF9 Raw number and proportion of respondents changing from incorrect to correct
answers
Guidelines acceptance Survey questions AA1-AA2
a Raw number and proportion of respondents changing from SD or D to SA or A
Outcomes expectation Case scenarios OE1-OE6 Raw number and proportion of respondents changing from incorrect to correct
answers
Implementation performance
measures
Qualitative exit interviews ≥75% positive statements
Capture of episodes of
bacteriuria
≥95% capture of episodes of bacteriuria
Delivery of audit and
feedback
≥80% delivery to correct provider
aKA measures knowledge awareness, KF measures knowledge familiarity, AA measures awareness acceptance, and OE measures outcome expectancy.
A = agree; D = disagree; SA = strongly agree; SD = strongly disagree.
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as items that measure attitudes and outcome expectan-
cies related to the guidelines. No standardized instru-
ment is available to assess physician-related barriers to
appropriate management of ABU. Our starting point
was prior surveys of management of hypertension [31]
and antibiotic-prescribing decisions for pneumonia [29].
We also found several qualitative studies concerning
prevention of CAUTI [34,35] and inappropriate use of
urinary catheters [36]. Two projects addressing unneces-
sary antibiotic use were also relevant: the “Do Bugs
Need Drugs” project in Canada [37] and the postpre-
scription antimicrobial review study mentioned in our
Background section above [38]. The principal investiga-
tor contacted the authors of these studies by email, by
telephone, and/or in person at national meetings to dis-
cuss appropriate survey design.
The survey instrument will have three sections. The
first section will be a cover letter. The cover letter
explains the purpose of the study to the healthcare pro-
viders and explains that their participation is entirely
voluntary, thus satisfying implied consent for participa-
tion. The second part of the survey is a cover sheet that
assesses provider demographics, such as level of train-
ing, type of training, etc. This cover sheet will have a
randomly generated number on it that will also appear
on each subsequent sheet of the survey. The cover sheet
with the provider’s identifiable information can then be
separated from the surveys to avoid bias in interpreta-
tion of survey results. The third section of the survey
contains the survey questions. These questions will
assess knowledge: degree of awareness of the existence
of the guidelines, familiarity with the guidelines’ content,
and confidence in that familiarity. Other questions will
measure physicians’ acceptance of the guidelines, and
we have also designed short patient scenarios to assess
outcome expectancy about the guidelines. Each case will
present a hospitalized patient with bacteriuria and a
chronic, indwelling urinary catheter. The cases will differ
in elements, such as the level of pyuria, the patient’sa g e
and comorbidities, the type of organism isolated from
the urine, the appearance or smell of the urine, the pre-
sence of specific urinary symptoms, and the presence of
v a g u es y s t e m i cc o m p l a i n t s .P r o v i d e r sw i l lb ea s k e d
whether they would or would not treat each case with
antibiotics. These cases are designed to address provi-
ders’ beliefs about the consequences of not treating bac-
teriuria (risk perception) and to elucidate which
elements drive the decision to treat/not treat bacteriuria.
Although we have built our survey on established mod-
els concerning antibiotic prescribing decisions, [29] our
survey instrument has been tailored to our specific clini-
cal issue (CAUTI) and, thus, will require pilot testing
with a selection of participants from the targeted groups
o fh e a l t h c a r ep r o v i d e r s .W ep l a nt oc o n d u c tc o g n i t i v e
interviews to assess clarity of wording, understandability
of items, and appropriateness of response options. We
will conduct preliminary analyses of responses given,
response-option use frequency, and floor/ceiling effects.
Results of these analyses will be used to further revise
items and response scales as necessary. We also will use
our pilot testing to develop questions that specifically
address social norms and self-efficacy.
Monitoring the success of the intervention
We plan to monitor the success of the intervention as we
proceed, which in itself is crucial to interpreting the out-
comes and ultimately disseminating the intervention to
other sites. We will administer brief exit interviews when
giving the postintervention surveys in years 2 and 3
(Table 2). In these interviews, we will informally assess
and address barriers to implementation that may arise
during the course of the study by asking providers about
their perception of the implementation efforts. Although
we do not expect these information surveys to result in
quantifiable data, they will help us customize our inter-
vention to local conditions in the various hospital units.
Analysis
Analysis plan and sample size for objective 1
Independent variables for objective 1 For the variables
in objective 1, it is important to understand that the
intervention is applied to the healthcare providers, but
Table 3 clinical outcomes for objective 1 in order of importance
Outcomes Measurement of change
a
Inappropriate treatment of CAABU Fewer episodes of CAABU treated inappropriately
Inappropriate collection of urine cultures from patients with CAABU Decreased number of urine cultures/1,000 catheter-days
Number of days antibiotics given for CAABU Fewer days of antibiotic use for CAABU
Use of urinary catheters Decreased urinary catheter-days/patient bed-days
Complications of inappropriate antibiotics Clostridium difficile colitis, emergence of resistant organisms
b
Complications of bacteriuria No increase in pyelonephritis or urosepsis
aComparisons are for the specific wards on the intervention facility and the corresponding wards on the control facility.
bIn 30 days following inappropriate
antibiotic use in a given patient.
CAABU = catheter-associated asymptomatic bacteriuria.
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teriuria occurring in catheterized inpatients (Table 3).
We will account for the correlation that may exist
among patients treated by the same healthcare provider
in our regression models. The independent variables
include age and gender of the patient, duration of cathe-
ter use, catheter type, hospital ward and service, types
and quantities of organisms found in the urine, number
of white blood cells (WBCs) in urine, number of WBCs
in the serum, and highest temperature in 24 hours
around the time of urine specimen collection.
Dependent variables for objective 1a–inappropriate
treatment The main outcome of interest for this objec-
tive is the number of cases of ABU that are managed
inappropriately out of all episodes of bacteriuria. This
determination will be made by applying the diagnostic
algorithm. The dependent variable to be used in the
analytic models will be whether or not each episode of
bacteriuria is managed inappropriately. The unit for
analysis will be episodes of bacteriuria.
A secondary outcome will be the number of days that
antibiotics are given to treat ABU. We will determine
the reason for treatment of bacteriuria (if stated in the
medical record), antibiotics given, and duration of treat-
ment. As a safety issue, we will monitor outcomes of
bacteriuria at both sites for 30 days following the epi-
sode. These outcomes will include any side effects of
the antibiotics given, isolati o no fa no r g a n i s mr e s i s t a n t
to the antibiotics given, or Clostridium difficile colitis.
We will also monitor for any complications that may
develop from bacteriuria, such as symptomatic UTI,
pyelonephritis, and urosepsis.
Dependent variables for objective 1b–inappropriate
screening For this objective, we are interested in
whether the intervention results in decreased screening
for ABU in catheterized patients. Screening for catheter-
associated ABU will be measured by the number of
urine cultures collected per days of catheter use. We
predict that as healthcare providers become more com-
fortable with leaving catheter-associated bacteriuria
untreated, they will recognize that urine cultures are fre-
quently unnecessary in catheterized patients and thus,
order fewer urine cultures. All urine cultures sent to the
microbiology laboratory from the study units will be
documented, whether positive or negative. We will cal-
culate the number of urine cultures collected per 100
catheter device-days for each unit.
A secondary outcome for objective 1b will be the fre-
quency of use of urinary catheters in hospitalized
patients. We will need to track this information, as our
intervention may have the unintentional but beneficial
effect of causing providers to remove unnecessary urin-
ary catheters. Therefore, we will also calculate the
number of catheter device-days per 100 patient bed-
days on each unit.
Estimated sample size for objective 1a–inappropriate
treatment We have estimated the sample size of epi-
sodes of bacteriuria needed at each of the two sites
based on testing the differences in two independent pro-
portions. The effect size to be detected is h =|1 - 2 |,
where  = 2 arcsine √P [39]. Preliminary analyses found
that the percentage of patients who received inappropri-
ate treatment was 36%. Assuming a two-sided test, a =
.05, and power of 80%, a sample size of 300 episodes is
needed at each site in order to detect an 11% reduction
in inappropriate treatment at the intervention site
(down to 25%) compared to the control site rate of 36%.
Specifically, p1 = .36, 1 = 1.287, p2 = .25, 2 = 1.047,
and h = .24, which represent a small effect size. On the
specific hospital units targeted in this study, there were
over 3,000 discharges associated with urinary catheteri-
zation from the study wards at the two sites combined
in fiscal year (FY) 2008. Thus, we should have adequate
power to detect differences between the intervention
and control sites. For the medicine units alone, we will
have enough power to detect whether there was a differ-
ence in inappropriate treatment between intervention
and control sites because there were approximately
1,600 patients at the Houston site estimated to have had
catheters in the non-ICU medical bed sections in
FY2008 and 1,300 unique patients in San Antonio.
Estimated sample size for objective 1b–inappropriate
screening We do not have estimates of the percentage
of catheterized patients who are screened for ABU. We
have based our estimates of the sample size on detecting
a reduction in the intervention group of 25% in the per-
centage of catheterized patients who are screened for
ABU. Based on estimates of the number of catheterized
patients at Houston and San Antonio in a one-year time
period (1,867 and 1,512, respectively), we will have 80%
power to detect a 25% reduction in percentage of
patients screened, even if the percentage of screened
patients is as low as 10%.
Analyses for objective 1
For the analysis of inappropriate treatment, we will test
for differences in the proportion of inappropriately trea-
ted episodes of bacteriuria between intervention and
control sites using a hierarchical regression approach.
Episodes will be nested within patients and patients
nested within provider. Independent variables will be
those described above. A significant value for the para-
meter estimate for the intervention will indicate that the
audit feedback group differed from the control group.
For the analysis of inappropriate screening, we will
conduct a logistical regression analysis in which the
dependent variable will be whether or not the
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archical models will allow nesting of patients within
provider. An indicator variable for the intervention
effect will be used to determine differences between the
audit feedback and control groups. Independent vari-
ables will include variables to indicate the unit in which
the patient was hospitalized in addition to patient-
related characteristics. A similar logistical analysis will
be run for the secondary outcome of whether or not the
hospitalized patient had a urinary catheter. For both the
primary and secondary outcomes, the number of cul-
tures per 100 device-days and the number of device-
days per 100 bed-days will be compared among the
units using analysis of covariance.
For the secondary outcome of days of inappropriate
antibiotic use, we will first examine the distribution of
the number of days that antibiotics were given. If the
distribution is not normally distributed, we will consider
appropriate transformations. In addition, we may con-
sider use of hierarchical Poisson regression models.
For the remaining dependent variables identified in
Table 3, when possible, we will test for differences
between the intervention and control using the hierarch-
ical regression approaches above. For rare outcomes for
which fewer than 10 total cases are expected, we may be
unable to conduct comparative analyses and will instead
provide descriptive analyses.
Analysis plan and sample size for objective 2
We expect to survey 100 providers at the MEDVAMC
in year 2, 100 providers at the MEDVAMC in year 3,
and 100 providers at the STVHCS in year 3, resulting in
300 paired pre/post surveys. We will calculate the raw
number and proportion of providers at each site whose
survey responses exhibit clinically meaningful change
(provider learning), as described in Table 2. Though we
recognize that this measurement process will be
exploratory, we expect the results to shed light on the
efficacy of the intervention from a provider perspective,
triangulating with improved clinical outcomes from
objective 1 and thus augmenting our overall rationale
for dissemination. We also intend to explore which of
the attributes measured in objective 2 are associated
most strongly with changes in clinical outcomes mea-
sured in objective 1 and to assess how well any empiri-
cal relationships are supported conceptually. Finally, we
will assess the empirical relationships between provider
learning and provider demographics.
To measure the success of the audit and feedback
system, we will document how many episodes of bac-
teriuria were audited (underwent medical-record
review), how many audited episodes resulted in feed-
back (a phone call or visit to the provider), and how
many episodes of feedback were delivered to the cor-
rect provider (someone directly involved in the
prescribing decisions for the patient). The information
about correct delivery of feedback will be particularly
important, and we expect the majority of the applica-
tion barriers to occur in this area. This assessment will
be made every three months by the research coordina-
tor. If fewer than 90% of episodes of bacteriuria receive
audit, or if fewer than 80% of audits are delivered to
the correct team within three days, we will reassess
our audit and feedback methods. These evaluation ele-
ments will be critical for developing implementation
and dissemination protocols.
Ethical approval
This study protocol has been approved by the institu-
tional review board at Baylor College of Medicine as
protocol H-24180, by the Research and Development
Committee at the Michael E. DeBakey Veterans Affairs
Medical Center as protocol 08K06.H, and by the Univer-
sity of Texas Health Science Center at San Antonio as
protocol HSC20100128H. This proposal was reviewed at
the August 2009 meeting of the Health Services
Research and Development Service (HSR&D) Scientific
Merit Review Board (SMRB), and the Board funded this
proposal as IIR-09-104.
Discussion
Our intervention is tightly focused on a specific aspect
of poor-quality care that has been observed in both our
specific setting [15] and in other hospitals throughout
the world [16]. We propose a strategy based on what
has been successful in analogous guideline-implementa-
tion research [38]. If successful, our proposed interven-
tion will significantly improve the quality of healthcare
delivered to hospitalized patients with urinary catheters.
Dissemination of our intervention could occur by mak-
ing it a component of the bladder bundle programs cur-
rently being introduced in hospitals throughout the
United States. In addition, studies evaluating the com-
parative and cost effectiveness of the individualized and
ward-level audit and feedback are needed.
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